FGFR2 and cholangiocarcinoma: Infigratinib (BGJ398) is a selective pan-FGFR inhibitor that was approved by the FDA on 29 May 2021 for the treatment of patients with previously treated, unresectable locally advanced, or metastatic CCA with fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.